NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

BioLife Solutions, Inc. (BLFS) Stock Analysis

BioLife Solutions, Inc. (BLFS) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

BLFS

$35.25

−$0.28 (−0.79%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BLFS with… →

BLFS Key Statistics

As of Sep 4, 2026
Trading
Open
$35.07
Previous Close
$35.53
Day's Range
34.89–35.52
52-Week Range
17.86–38.10
Volume
344.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.92
Valuation
Market Cap
$1.72B
P/E Ratio
35.25
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
106.82
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
15.09
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
16.16
EPS (ttm)Profit attributable to each share over the last twelve months.
1.00
Financials (FY)
Revenue (FY)
$96.21M+28.89%
Net Income (FY)
−$4.60M
Profit marginThe share of revenue left as profit after all costs and taxes.
54.35%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.91M
1-Year Return
+36.26%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.11M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

BLFS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+45.78%
2025−6.86%
2024+59.75%
2023−10.71%
2022−51.17%
2021−6.57%
2020+146.54%
2019+34.50%
2018+100.50%
2017+272.67%
2016 (partial year)−15.26%

As of September 4, 2026.

BLFS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$96.21M−$4.60M−4.8%
2024$74.65M−$20.18M−27.0%
2023$68.02M−$68.00M−100.0%
2022$76.24M−$139.81M−183.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$96.21M$62.12M−$16.60M−$4.60M−4.8%
2024$74.65M$50.10M−$4.48M−$20.18M−27.0%
2023$68.02M$41.32M−$19.40M−$68.00M−100.0%
2022$76.24M$46.91M−$10.68M−$139.81M−183.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BLFS Valuation vs Medical Instruments & Supplies Median

Median of 55 stocks
MetricBLFSMedical Instruments & Supplies medianvs median
P/E35.2535.611% below
P/S ratio16.163.175.1x the median
Profit margin54.35%0.85%53.5 pts above

Medians across 55 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BioLife Solutions, Inc. (BLFS) carries a market capitalisation of $1.72B. The company sits in the Healthcare sector, in the Medical Instruments & Supplies industry. Headcount on file is 155.

Over the past 52 weeks the price has ranged from $17.86 to $38.10. The most recent close on file for BLFS is $35.25, dated September 4, 2026. That is −$0.28 (−0.79%) against the previous close. The latest close sits 97.37% above that 52-week low.

Financial Health

In fiscal 2025, BioLife Solutions, Inc. reported revenue of $96.21M. That is +28.89% against the prior fiscal year, when revenue was $74.65M. The same year closed with a net loss of $4.60M. Profit margin runs at 54.35%. That is 53.5 percentage points above the Medical Instruments & Supplies median of 0.85%. Earnings per share on a trailing basis come to 1.

Across the 4 fiscal years on file, revenue moves from $76.24M in 2022 to $96.21M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

BLFS trades at a trailing price-to-earnings ratio of 35.25. That is 1.02% below the Medical Instruments & Supplies median of 35.61. On forward earnings the ratio is 106.82. The PEG ratio, which sets the P/E against expected earnings growth, reads 15.09. The price-to-sales ratio is 16.16. On price-to-sales that is 5.1 times the Medical Instruments & Supplies median of 3.17. The medians here are taken across 55 Medical Instruments & Supplies companies that report the metric.

Beta against the wider market is reported at 1.92. Daily returns over the trailing 10 years annualize to a volatility of 65.74%. Over the trailing twelve months the price has returned +36.26%. Across 10 years the annualized return works out at +35.26%.

Growth & Income

No dividend is on file for BLFS.

2026 is still running; the price is +45.78% year to date. Across the complete calendar years on file, 2017 returned +272.67% and 2022 returned −51.17%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

BioLife Solutions, Inc. (BLFS) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BioLife Solutions, Inc. BLFS $1.72B 35.3
Intuitive Surgical, Inc. ISRG $131.38B 42.4
Becton, Dickinson and Company BDX $50.32B 32.0
Medline Inc. MDLN $49.23B 45.7

The Medical Instruments & Supplies industry average P/E ratio is 35.6x. BioLife Solutions, Inc. trades at a P/E of 35.3.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$131.38B

 BDX

Becton, Dickinson and Company

$50.32B

 MDLN

Medline Inc.

$49.23B

 ALC

Alcon Inc.

$34.08B

 RMD

ResMed Inc.

$32.94B

 WST

West Pharmaceutical Services, Inc.

$23.93B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About BioLife Solutions, Inc.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

Visit website →